TDMS Study 05069-07 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE
NTP Experiment-Test: 05069-07 Report: PEIRPT05
Study Type: CHRONIC Date: 10/19/94
Route: DERMAL,SOLUTION Time: 16:12:20
CORE STUDY
Facility: TSI Mason Research
Chemical CAS #: 147-47-7
Lock Date: 08/05/92
Cage Range: All
Reasons For Removal: 25022 Accidently Killed 25019 Moribund Sacrifice
25020 Natural Death 25021 Terminal Sacrifice
Removal Date Range: All
Treatment Groups: Include 002 0 MG/KG
Include 004 3.6 MG/KG
Include 006 6.0 MG/KG
Include 008 10.0 MG/KG
Include 001 0 MG/KG
Include 003 3.6 MG/KG
Include 005 6.0 MG/KG
Include 007 10.0 MG/KG
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05069-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 10/19/94
Route: DERMAL,SOLUTION Time: 16:12:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 3.6 6.0 10.0
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Early Deaths
Moribund Sacrifice 6 7 7 6
Natural Death 10 3 3 4
Accidently Killed 1
Survivors
Terminal Sacrifice 34 40 40 40
Animals Examined Microscopically 50 50 51 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (43) (47) (48) (45)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Intestine Large, Colon (49) (50) (51) (49)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Intestine Large, Rectum (49) (50) (51) (49)
Carcinoma, Metastatic, Kidney 1 (2%)
Intestine Large, Cecum (49) (49) (50) (49)
Carcinoma, Metastatic, Kidney 1 (2%)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Intestine Small, Duodenum (45) (49) (50) (49)
Polyp Adenomatous 1 (2%)
Intestine Small, Jejunum (44) (47) (51) (49)
Carcinoma, Metastatic, Kidney 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Intestine Small, Ileum (45) (49) (49) (48)
Carcinoma, Metastatic, Kidney 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Liver (50) (50) (51) (50)
Cholangiocarcinoma 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%)
Hemangiosarcoma, Multiple 1 (2%)
Hepatocellular Carcinoma 12 (24%) 8 (16%) 5 (10%) 11 (22%)
Hepatocellular Carcinoma, Multiple 1 (2%) 1 (2%) 2 (4%)
Hepatocellular Adenoma 21 (42%) 8 (16%) 13 (25%) 11 (22%)
Hepatocellular Adenoma, Multiple 9 (18%) 14 (28%) 8 (16%) 7 (14%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Mesentery (9) (8) (11) (8)
Cholangiocarcinoma, Metastatic, Liver 1 (13%)
Hemangioma 1 (13%)
Page 2
NTP Experiment-Test: 05069-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 10/19/94
Route: DERMAL,SOLUTION Time: 16:12:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 3.6 6.0 10.0
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Hepatocellular Carcinoma, Metastatic, Liver 1 (9%)
Histiocytic Sarcoma 1 (11%)
Pancreas (50) (50) (51) (50)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Salivary Glands (50) (49) (51) (50)
Stomach, Forestomach (50) (50) (51) (50)
Squamous Cell Papilloma 1 (2%) 1 (2%)
Stomach, Glandular (50) (50) (51) (50)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (51) (50)
Carcinoma, Metastatic, Kidney 1 (2%)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (48) (49) (51) (50)
Adenoma 1 (2%)
Carcinoma, Metastatic, Kidney 1 (2%)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Capsule, Adenoma 1 (2%) 1 (2%)
Capsule, Hepatocellular Carcinoma,
Metastatic, Liver 1 (2%)
Adrenal Medulla (48) (49) (49) (50)
Carcinoma, Metastatic, Kidney 1 (2%)
Histiocytic Sarcoma 1 (2%)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (49) (50) (51) (50)
Adenoma 1 (2%) 1 (2%) 1 (2%)
Pituitary Gland (44) (48) (47) (45)
Pars Distalis, Adenoma 5 (11%) 4 (8%) 6 (13%) 4 (9%)
Pars Distalis, Carcinoma 1 (2%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (49) (50) (50) (50)
C-Cell, Adenoma 1 (2%)
C-Cell, Carcinoma 1 (2%)
Page 3
NTP Experiment-Test: 05069-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 10/19/94
Route: DERMAL,SOLUTION Time: 16:12:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 3.6 6.0 10.0
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Follicular Cell, Adenoma 1 (2%) 2 (4%) 3 (6%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (50) (49) (50) (49)
Carcinoma 1 (2%)
Carcinoma, Metastatic, Kidney 1 (2%)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Cystadenoma 1 (2%) 2 (4%)
Granulosa Cell Tumor Benign 1 (2%)
Hemangioma 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Thecoma Malignant 1 (2%)
Uterus (50) (50) (51) (50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Polyp Stromal 2 (4%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (51) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymph Node (8) (4) (5) (3)
Sarcoma, Metastatic, Skin 1 (33%)
Mediastinal, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (13%) 1 (33%)
Pancreatic, Hemangioma 1 (25%)
Pancreatic, Sarcoma, Metastatic, Skin 1 (13%)
Lymph Node, Mandibular (50) (49) (51) (50)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymph Node, Mesenteric (47) (48) (51) (50)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Hemangioma 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Spleen (50) (50) (51) (50)
Hemangiosarcoma 1 (2%) 1 (2%) 2 (4%)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Page 4
NTP Experiment-Test: 05069-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 10/19/94
Route: DERMAL,SOLUTION Time: 16:12:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 3.6 6.0 10.0
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Thymus (45) (46) (48) (49)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Thymoma Malignant 1 (2%)
Mediastinum, Carcinoma, Metastatic, Kidney 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (48) (50) (49)
Carcinoma 1 (2%) 1 (2%)
Skin (50) (50) (51) (50)
Sarcoma 1 (2%)
Skin, Site of Application, Keratoacanthoma 1 (2%)
Subcutaneous Tissue, Hemangioma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma 2 (4%) 2 (4%) 1 (2%)
Subcutaneous Tissue, Schwannoma Malignant 1 (2%)
Subcutaneous Tissue, Skin, Site of
Application, Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (51) (50)
Vertebra, Hemangiosarcoma 1 (2%)
Skeletal Muscle (3) (1) (1) (1)
Cholangiocarcinoma, Metastatic, Liver 1 (100%)
Hemangiosarcoma 1 (100%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (100%)
Sarcoma, Metastatic, Skin 1 (33%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (51) (50)
Carcinoma, Metastatic, Pituitary Gland 1 (2%)
Spinal Cord (1) (2) (1)
Hemangiosarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
Page 5
NTP Experiment-Test: 05069-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 10/19/94
Route: DERMAL,SOLUTION Time: 16:12:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 3.6 6.0 10.0
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (51) (50)
Alveolar/Bronchiolar Adenoma 3 (6%) 6 (12%) 2 (4%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 2 (4%)
Alveolar/Bronchiolar Carcinoma 3 (6%) 2 (4%) 2 (4%) 2 (4%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%) 1 (2%)
Carcinoma, Metastatic, Kidney 1 (2%)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Hemangiosarcoma, Metastatic, Heart 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 3 (6%) 6 (12%) 2 (4%) 9 (18%)
Hepatocellular Carcinoma, Metastatic, Lung 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Mediastinum, Hemangiosarcoma 1 (2%)
Nose (50) (49) (51) (50)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (1) (3) (1)
Adenoma 1 (100%) 2 (67%)
Carcinoma 1 (33%) 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (51) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Renal Tubule, Carcinoma 1 (2%)
Urinary Bladder (50) (50) (51) (49)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(51) *(50)
Histiocytic Sarcoma 4 (8%) 1 (2%)
Lymphoma Malignant 10 (20%) 9 (18%) 13 (25%) 9 (18%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 05069-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 10/19/94
Route: DERMAL,SOLUTION Time: 16:12:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 3.6 6.0 10.0
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 46 40 41 39
Total Primary Neoplasms 85 69 74 64
Total Animals with Benign Neoplasms 34 30 29 24
Total Benign Neoplasms 43 41 43 32
Total Animals with Malignant Neoplasms 31 22 26 28
Total Malignant Neoplasms 42 28 31 32
Total Animals with Metastatic Neoplasms 7 7 4 13
Total Metastatic Neoplasm 21 9 16 26
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 05069-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 10/19/94
Route: DERMAL,SOLUTION Time: 16:12:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 3.6 6.0 10.0
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Early Deaths
Natural Death 6 8 2 10
Moribund Sacrifice 5 4 7 3
Accidently Killed 1
Survivors
Terminal Sacrifice 39 37 41 37
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (50) (50) (50) (50)
Gallbladder (46) (46) (47) (41)
Carcinoma, Metastatic, Pancreas 1 (2%)
Intestine Large, Colon (48) (48) (50) (49)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Intestine Large, Cecum (48) (50) (50) (46)
Carcinoma 1 (2%)
Intestine Small, Duodenum (47) (45) (49) (46)
Intestine Small, Jejunum (47) (46) (49) (45)
Intestine Small, Ileum (45) (46) (47) (44)
Liver (50) (50) (50) (50)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Hemangiosarcoma 2 (4%) 3 (6%) 2 (4%)
Hemangiosarcoma, Multiple 1 (2%) 1 (2%) 1 (2%)
Hepatoblastoma 1 (2%) 2 (4%)
Hepatocellular Carcinoma 5 (10%) 7 (14%) 5 (10%) 9 (18%)
Hepatocellular Carcinoma, Multiple 3 (6%) 4 (8%)
Hepatocellular Adenoma 14 (28%) 17 (34%) 12 (24%) 16 (32%)
Hepatocellular Adenoma, Multiple 10 (20%) 13 (26%) 13 (26%) 10 (20%)
Hepatocholangiocarcinoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Mesentery (1) (2) (3)
Carcinoma, Metastatic, Uncertain Primary Site 1 (33%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (50%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (33%)
Pancreas (49) (49) (50) (49)
Carcinoma 1 (2%)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Hemangioma 1 (2%)
Page 8
NTP Experiment-Test: 05069-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 10/19/94
Route: DERMAL,SOLUTION Time: 16:12:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 3.6 6.0 10.0
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Histiocytic Sarcoma 1 (2%)
Salivary Glands (50) (49) (50) (50)
Stomach, Forestomach (49) (50) (50) (48)
Squamous Cell Carcinoma 2 (4%) 1 (2%) 1 (2%)
Squamous Cell Papilloma 1 (2%)
Stomach, Glandular (48) (50) (50) (48)
Carcinoid Tumor Benign 1 (2%)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Hemangioma 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (49) (49) (49) (50)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Capsule, Adenoma 3 (6%) 1 (2%)
Adrenal Medulla (48) (49) (49) (50)
Pheochromocytoma Benign 1 (2%) 1 (2%)
Pituitary Gland (45) (43) (40) (46)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (49) (50) (50) (50)
Follicular Cell, Adenoma 2 (4%) 1 (2%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (49) (50) (50) (50)
Carcinoma, Metastatic, Pancreas 1 (2%)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Preputial Gland (48) (50) (50) (50)
Hemangiosarcoma 1 (2%)
Prostate (49) (50) (50) (50)
Page 9
NTP Experiment-Test: 05069-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 10/19/94
Route: DERMAL,SOLUTION Time: 16:12:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 3.6 6.0 10.0
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Seminal Vesicle (49) (50) (50) (50)
Carcinoma, Metastatic, Pancreas 1 (2%)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Testes (49) (50) (50) (50)
Carcinoma, Metastatic, Pancreas 1 (2%)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Interstitial Cell, Adenoma 1 (2%) 1 (2%) 1 (2%) 3 (6%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (49) (50) (49)
Hemangiosarcoma 2 (4%) 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Lymph Node (2) (3) (1) (2)
Pancreatic, Histiocytic Sarcoma 1 (50%)
Lymph Node, Mandibular (49) (48) (49) (48)
Lymph Node, Mesenteric (48) (47) (50) (47)
Carcinoma, Metastatic, Pancreas 1 (2%)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Spleen (48) (49) (49) (50)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Hemangiosarcoma 2 (4%) 2 (4%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Thymus (39) (42) (46) (40)
Thymoma NOS 1 (3%)
Mediastinum, Hemangioma 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (50)
Sarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 05069-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 10/19/94
Route: DERMAL,SOLUTION Time: 16:12:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 3.6 6.0 10.0
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (49) (50) (49)
Osteosarcoma 1 (2%)
Skeletal Muscle (1) (3)
Carcinoma, Metastatic, Uncertain Primary Site 1 (33%)
Hemangioma 1 (33%)
Hemangiosarcoma 1 (100%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (33%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 8 (16%) 7 (14%) 11 (22%) 8 (16%)
Alveolar/Bronchiolar Adenoma, Multiple 4 (8%) 1 (2%) 2 (4%)
Alveolar/Bronchiolar Carcinoma 6 (12%) 5 (10%) 7 (14%) 6 (12%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%) 1 (2%) 1 (2%) 2 (4%)
Carcinoma, Metastatic, Pancreas 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (4%) 1 (2%) 2 (4%) 6 (12%)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Nose (50) (50) (50) (50)
Hemangiosarcoma 1 (2%)
Trachea (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (4) (5) (5) (3)
Adenoma 3 (75%) 5 (100%) 3 (60%) 1 (33%)
Carcinoma 1 (20%) 1 (33%)
Bilateral, Carcinoma 1 (33%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (4%)
Histiocytic Sarcoma 1 (2%)
Page 11
NTP Experiment-Test: 05069-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 10/19/94
Route: DERMAL,SOLUTION Time: 16:12:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 3.6 6.0 10.0
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - cont
Renal Tubule, Adenoma 1 (2%) 1 (2%)
Renal Tubule, Carcinoma 1 (2%) 1 (2%) 1 (2%)
Urinary Bladder (49) (50) (50) (46)
Hemangioma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymphoma Malignant 3 (6%) 5 (10%) 2 (4%) 3 (6%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 12
NTP Experiment-Test: 05069-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE Date: 10/19/94
Route: DERMAL,SOLUTION Time: 16:12:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 3.6 6.0 10.0
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 42 41 43 46
Total Primary Neoplasms 74 76 75 79
Total Animals with Benign Neoplasms 35 33 35 34
Total Benign Neoplasms 43 46 51 43
Total Animals with Malignant Neoplasms 22 24 20 28
Total Malignant Neoplasms 30 30 24 36
Total Animals with Metastatic Neoplasms 2 1 3 8
Total Metastatic Neoplasm 2 1 9 31
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 13
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------